UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.